OR WAIT 15 SECS
© 2020 MJH Life Sciences and Pharmaceutical Executive. All rights reserved.
While the 1984 Act has been a boon for lower-cost generics, its goal of incentivizing new drug discovery has failed.
On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case.